Pharmaceutical class: Antineoplastic agents - monoclonal antibodies
Active compound: Brentuximab vedotin
SmPC: Click here
Adcetris is the only CD30-targeted therapy approved for patients with HL, sALCL & CTCL
Reimbursed indications of Adcetris
Download the Adcetris reimbursement form for Frontline HL & Frontline sALCL
Download the Adcetris reimbursement form for R/R HL & sALCL
Download the Adcetris reimbursement form for MF & PcALCL
- Adult patients 18+
- Hodgkin lymphoma
- Previously untreated CD30+ Stage IV Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine and dacarbazine (AVD).
- Consolidation for patients at high risk of relapse after ASCT, with high risk defined as the presence of ≥ 2 of the below risk factors
- Relapsed or progressive HL that occurred <12 months after first-line therapy or HL that was refractory for first-line therapy
- Best response of PR or SD to the most recent salvage therapy as determined by CT and/or PET scan,
- Extranodal disease in relapse pre-ASCT,
- B-symptoms in case of relapsed pre-ASCT,
- Two or more previous salvage therapies
- Relapsed or refractory CD30+ HL:
- following autologous stem cell transplant (ASCT) or
- following ≥ 2 prior therapies when ASCT or multi-agent chemotherapy is not a treatment option - Retreatment after initial Adcetris treatment if the patient meets all the below conditions
- Obtained a CR or PR with initial adcetris treatment
- Stopped initial treatment with adcetris during remission period
- Has experienced progression or relapse
- Systemic anaplastic large cell lymphoma
- Previously untreated ALK-positive (IPI ≥ 2) or ALK -negative (all IPI) CD30+ sALCL in combination with CHP
- Relapsed or refractory CD30+ sALCL
- Retreatment after initial adcetris treatment if the patient meets all the below conditions
- Obtained a CR or PR with initial adcetris treatment
- Stopped initial treatment with adcetris during remission period
- Has experienced progression or relapse
- Cutaneous T-cell Lymphoma
- CD30+ Mycosis Fungoides MF & primary cutaneous anaplastic large cell lymphoma pcALCL after failure of ≥ 2 systemic therapies incl. interferon-alfa, bexarotene, methotrexate, a combination of these or documented intolerance.
EARLY PATIENT ACCESS - Adcetris pre-approval
To ensure that patients have access to Adcetris as quickly as possible, Takeda offers you the possibility of obtaining an opinion on the reimbursement prior to the official reimbursement notification of the health insurance.
Takeda commits to pay the cost to cover the treatment from the approval of the pre-approval to the refusal of the orphan college. With the approval of the college, the cost of treatment will be borne by the health insurance.
The assessment of the pre-approval is done by the medical department and based on anonymized patient data. The request should be sent to: medical.department@takeda.com
PRACTICAL DETAILS OF ADCETRIS
- Available dosage & packaging:
1 x 50mg powder for concentrate for solution for infusion.
Pack of 1 vial, each vial contains 50 mg of brentuximab vedotin.
- Dosing and administration:
- Frontline HL & Frontline sALCL
- RRHL & RRsALCL
- MF & pcALCL
Download the dosing and administration recommandations for the reimbursed indications:
PRICE Download price information on Adcetris
C-APROM/BE/ADCE/0097